Tomoyuki Nishida
About
Tomoyuki Nishida is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery.
According to data from OpenAlex, Tomoyuki Nishida has authored 26 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Tomoyuki Nishida's work include Diabetes Treatment and Management (25 papers), Diabetes Management and Research (21 papers) and Metabolism, Diabetes, and Cancer (12 papers). Tomoyuki Nishida is often cited by papers focused on Diabetes Treatment and Management (25 papers), Diabetes Management and Research (21 papers) and Metabolism, Diabetes, and Cancer (12 papers). Tomoyuki Nishida collaborates with scholars based in Japan, Denmark and United Kingdom. Tomoyuki Nishida's co-authors include Kohei Kaku, Yutaka Seino, Jeppe Zacho, Toshimasa Yamauchi, Takashi Kadowaki, Soo Lim, Usman Khalid, Wataru Ogawa, Joakim Isendahl and Sang Yeoup Lee and has published in prestigious journals such as New England Journal of Medicine, Diabetologia and The Lancet Diabetes & Endocrinology.
In The Last Decade
Tomoyuki Nishida
25 papers receiving 708 citations
Hit Papers
Peers
Tomoyuki Nishida
Jessie L. Fahrbach United States
Raymond de la Rosa Denmark
Milivoj Piletič Denmark
Charles Atisso United States
Magnus F.G. Grøndahl Denmark
Bryan Goldman Denmark
Nor Azmi Kamaruddin Malaysia
Federico Pérez Manghi United States
Elisabeth Niemoeller Germany
Citations per year, relative to Tomoyuki Nishida Tomoyuki Nishida (= 1×)
peers
Jessie L. Fahrbach
Countries citing papers authored by Tomoyuki Nishida
Since
Specialization
Citations
This map shows the geographic impact of Tomoyuki Nishida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoyuki Nishida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoyuki Nishida more than expected).
Fields of papers citing papers by Tomoyuki Nishida
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tomoyuki Nishida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoyuki Nishida. The network helps show where Tomoyuki Nishida may publish in the future.
Co-authorship network of co-authors of Tomoyuki Nishida
This figure shows the co-authorship network connecting the top 25 collaborators of Tomoyuki Nishida. A scholar is included among the top collaborators of Tomoyuki Nishida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoyuki Nishida. Tomoyuki Nishida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Nishida, Tomoyuki, et al.. (2025). Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial. Obesity Research & Clinical Practice. 19(2). 146–153.
2.
Lingvay, Ildiko, Liming Chen, Esteban Jódar, et al.. (2025). Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia. 68(4). 739–751.
3.
Eto, Takashi, Miwa Haranaka, Niels Rode Kristensen, et al.. (2024). Pharmacological characteristics of once‐weekly insulin icodec in Japanese individuals with type 1 diabetes. Journal of Diabetes Investigation. 16(3). 434–441.
4.
Watada, Hirotaka, et al.. (2024). Efficacy and safety of once‐weekly insulin icodec versus once‐daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials. Diabetes Obesity and Metabolism. 26(12). 5882–5895.
5.
Bergenstal, Richard M., Björg Ásbjörnsdóttir, Sara Kehlet Watt, et al.. (2024). Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1. The Lancet Diabetes & Endocrinology. 12(11). 799–810.
6.
Kadowaki, Takashi, Sang Yeoup Lee, Wataru Ogawa, et al.. (2024). Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis. Obesity Research & Clinical Practice. 18(6). 457–464.
7.
Rosenstock, Julio, Stephen C. Bain, Amoolya Gowda, et al.. (2023). Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. New England Journal of Medicine. 389(4). 297–308.
8.
Kadowaki, Takashi, Joakim Isendahl, Usman Khalid, et al.. (2022). Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 10(3). 193–206.
9.
Araki, Eiichi, Shin‐ichi Harashima, Tomoyuki Nishida, & Jiro Nakamura. (2022). Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis. Journal of Diabetes Investigation. 13(12). 1971–1980.
10.
Yabe, Daisuke, Yuichiro Yamada, Kohei Kaku, et al.. (2022). Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index. Journal of Diabetes Investigation. 13(7). 1161–1174.
11.
Komatsu, Mitsuhisa, et al.. (2021). Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials. Journal of Diabetes Investigation. 12(9). 1610–1618.
12.
Kaku, Kohei, Yuichiro Yamada, Hirotaka Watada, et al.. (2018). Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Diabetes Obesity and Metabolism. 20(5). 1202–1212.
13.
Ikushima, Ippei, Lene Jensen, Anne Flint, et al.. (2018). A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Advances in Therapy. 35(4). 531–544.
14.
Seino, Yutaka, Yasuo Terauchi, Takeshi Osonoi, et al.. (2017). Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in J apanese people with type 2 diabetes. Diabetes Obesity and Metabolism. 20(2). 378–388.
15.
Ono, Yusuke, et al.. (2016). A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects. Diabetology International. 7(4). 404–412.
16.
Osonoi, Takeshi, et al.. (2015). Insulin degludec versus insulin glargine, both once daily as add-on to existing orally administered antidiabetic drugs in insulin-naive Japanese patients with uncontrolled type 2 diabetes: subgroup analysis of a pan-Asian, treat-to-target phase 3 trial. Diabetology International. 7(2). 141–147.
17.
Iwamoto, Yasuhiko, Per Clauson, Tomoyuki Nishida, & Kohei Kaku. (2012). Insulin degludec in J apanese patients with type 1 diabetes mellitus: A randomized controlled trial. Journal of Diabetes Investigation. 4(1). 62–68.
18.
Seino, Yutaka, Mads Frederik Rasmussen, Tomoyuki Nishida, & Kohei Kaku. (2011). Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial. Journal of Diabetes Investigation. 2(4). 280–286.
19.
Kaku, Kohei, Mads Frederik Rasmussen, Tomoyuki Nishida, & Yutaka Seino. (2011). Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. Journal of Diabetes Investigation. 2(6). 441–447.
20.
Kadowaki, Takashi, Tomoyuki Nishida, & Kohei Kaku. (2010). 28‐week, randomized, multicenter, open‐label, parallel‐group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice‐daily injections vs twice‐daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes. Journal of Diabetes Investigation. 1(3). 103–110.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jessie L. Fahrbach Breakdown of academic impact, for papers by Juan José Gorgojo Martínez Breakdown of academic impact, for papers by Raymond de la Rosa Breakdown of academic impact, for papers by Milivoj Piletič Breakdown of academic impact, for papers by Charles Atisso Breakdown of academic impact, for papers by Magnus F.G. Grøndahl Breakdown of academic impact, for papers by Bryan Goldman Breakdown of academic impact, for papers by Nor Azmi Kamaruddin Breakdown of academic impact, for papers by Federico Pérez Manghi Breakdown of academic impact, for papers by Elisabeth Niemoeller